DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting November 23, 2015 • 8:05 AM EST
DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015 November 19, 2015 • 8:05 AM EST
DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update November 17, 2015 • 8:05 AM EST
DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers November 13, 2015 • 7:35 AM EST
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors November 11, 2015 • 7:35 AM EST
DelMar Pharmaceuticals Collaborators Present Data on the Unique Molecular Mechanisms Responsible for VAL-083 Activity Against Cancer November 10, 2015 • 8:05 AM EST
DelMar Pharmaceuticals to Present Updated Phase II Safety and Efficacy Data on VAL-083 in Refractory Glioblastoma Multiforme November 9, 2015 • 4:01 PM EST
DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) November 6, 2015 • 12:15 PM EST
DelMar Pharmaceuticals to Present at the SeeThruEquity Microcap Investor Forum on November 12, 2015 November 5, 2015 • 9:15 AM EST
DelMar Pharmaceuticals Announces the Completion of Enrollment in its Phase II Expansion Study of VAL-083 in Refractory Glioblastoma Multiforme October 21, 2015 • 8:05 AM EDT